Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : A US National Health Care System? -- Ignore unavailable to you. Want to Upgrade?

To: Lane3 who wrote (8614)	8/23/2009 9:06:08 AM
From: Alastair McIntosh	Read Replies (1) \| Respond to of 42652

My own sense is that $50K per year for life, however long that may last, is too much to expect from any but high-end private insurance. It appears that NICE in Great Britain uses about $50,000/QALY as a benchmark for cancer treatment. A different drug for a different cancer, however The acceptability curve for this analysis demonstrates a > 90% probability that the cost per QALY gained with 'Arimidex' would be lower than the £30,000 threshold established by NICE for commonly used cancer treatments. medicalnewstoday.com Lots of information from seaching [QALY "markov model"] O.T. I thought that I had a decent vocabulary but I had to look up "dysphemistic".